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Abstract
Background: Post processing for brain spectra has a great influence on the fit quality of individual spectra, as well
as on the reproducibility of results from comparable spectra. This investigation used pairs of spectra, identical in
system parameters, position and time assumed to differ only in noise. The metabolite amplitudes of fitted time
domain spectroscopic data were tested on reproducibility for the main brain metabolites.
Methods: Proton spectra of white matter brain tissue were acquired with a short spin echo time of 30 ms and a
moderate repetition time of 1500 ms at 1.5 T. The pairs were investigated with one time domain post-processing
algorithm using different parameters. The number of metabolites, the use of prior knowledge, base line parameters
and common or individual damping were varied to evaluate the best reproducibility.
Results: The protocols with most reproducible amplitudes for N-acetylaspartate, creatine, choline, myo-inositol and
the combined Glx line of glutamate and glutamine in lesion free white matter have the following common
features: common damping of the main metabolites, a baseline using only the points of the first 10 ms, no
additional lipid/macromolecule lines and Glx is taken as the sum of separately fitted glutamate and glutamine. This
parameter set is different to the one delivering the best individual fit results.
Discussion: All spectra were acquired in “lesion free” (no lesion signs found in MR imaging) white matter. Spectra
of brain lesions, for example tumors, can be drastically different. Thus the results are limited to lesion free brain
tissue. Nevertheless the application to studies is broad, because small alterations in brain biochemistry of lesion free
areas had been detected nearby tumors, in patients with multiple sclerosis, drug abuse or psychiatric disorders.
Conclusion: Main metabolite amplitudes inside healthy brain can be quantified with a normalized root mean
square deviation around 5 % using CH3 of creatine as reference. Only the reproducibility of myo-inositol is roughly
twice as bad. The reproducibility should be similar using other references like internal or external water for an
absolute concentration evaluation and are not influenced by relaxation corrections with literature values.
Background
Nuclear magnetic resonance spectroscopy has developed
over the last decades as one of the exciting fields in
medical physics for the non-invasive measurement of
molecular concentrations inside the body [1–7]. In
principle the method is widely available at magnetic res-
onance imaging (MRI) units with field strengths above
1 T but its application is restricted for two main reasons.
Although data acquisition can be performed automatic-
ally for optimal results an experienced operator is neces-
sary. Additionally no standard post processing of the
acquired data exists [8]. This investigation tries to en-
hance the post processing towards reproducible results
by varying the post processing parameters for identically
acquired spectra pairs.
Biochemical concentrations inside specific body regions
can be evaluated by fitting magnetic resonance spectro-
scopic data using model signals of the metabolites to be
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quantified. The fit algorithm detects metabolites with a
fair signal to noise ratio and sufficient long spin-spin re-
laxation time T2 in relation to the echo time TE. Metabo-
lites with short T2’s (broad lines) are hardly separable and
combined as baseline.
Metabolite model signals in time domain have the fol-
lowing parameters adjustable by the fit algorithm: ampli-
tude (corresponding to the area under a line in
frequency domain data), frequency (ppm position),
damping (line width) and phase (influencing the line
shape in frequency domain) [9–11]. The adoption of
“prior knowledge” can reduce the number of adjustable
parameters and/or restrict them to a certain region. For
example: the metabolite frequency is fixed to another
metabolite or limited to a region around the theoretical
value; the metabolites completely or partly have a com-
mon damping or phase.
Fit procedures for spectral data adjust the parameters
for the specified metabolites to minimize χ2 respecting
all prior knowledge restrictions. Usually, χ2 in time do-
main is defined as the sum Σi |Δi|
2, where Δi is the dif-
ference between measured value and fit value for the
data point sampled at time ti. If the assumed errors σi of
the measured values are not identical for all i, χ2 is taken
as Σi |Δi/σi|
2 to weight data points according to the error
σi in measurement i. For the ideal case, fitting of all me-
tabolites with appropriate parameters should result in a
difference between fit and the acquired signal around
zero containing the pure noise signal. This ideal case is
not achievable, because signals can be masked by noise,
they can overlay each other or signals with low T2
(broad lines) are not completely represented by the base
line. But it is evident that a flat difference line with a
low χ2 can be easily achieved using a large parameter set
(i. e. using many metabolites with all four parameters of
each metabolite freely adjustable).
Until today no commonly accepted post processing ex-
ists to quantify concentrations. Firstly, frequency [12] or
time domain models [10, 11] can be used for the appro-
priate data. Secondly, a decision is necessary on the me-
tabolites taken into account and on the restrictions of
each metabolite’s post processing parameters by the use
of prior knowledge.
For a series of acquisitions the fit quality can be rated
by the mean of all χ2. Using different metabolite sets
with varying post-processing parameters can detect a
minimal mean χ2. A large set of metabolites with unre-
stricted parameters decreases each χ2 and hence also the
mean of all χ2’s. But such a parameter setting not neces-
sarily is the one evaluating metabolite concentrations
with the best reproducibility. A post processing with a
good reproducibility should compute nearly identical
metabolite concentrations for data known to have the
same metabolite basis.
As approach for the preparation of in vivo data, differ-
ing only in noise, ideally a complete acquisition with 2 N
additions is divided in two acquisitions with N additions.
The two spectra for comparison build a pair consisting
of the sum of all even and the sum of all odd acquired
signals. The spectra of this procedure are as reprodu-
cible as possible for in vivo acquisitions. The MR-system
software did not allow adding even and odd excitations
to summed signals. Instead the two spectra of a pair
were acquired directly consecutively with the same sys-
tem parameters at an identical position and time point
(identical in time with respect to physiological concen-
tration changes). As long as the investigated subject did
not move within the two acquisitions this should match
the best achievable reproducibility for in vivo spectros-
copy. For the comparison it is assumed to have a pair of
two spectra formed by an identical metabolite basis
overlaid with different noise. The post processing should
evaluate similar results for the main (clearly visible)
metabolites.
This investigation concentrates on one post processing
software package metabolite report [9, 13, 14], mostly
identical to the new product software “syngo via” from
Siemens Healthcare (Erlangen, Germany) neglecting all
aspects and discussions on acquisition schemes or com-
parisons to other post processing algorithms.
The purpose of this paper is to achieve a good repro-
ducibility of the major metabolite amplitudes from the
acquired pairs of in vivo spectra by adjusting the post
processing fit parameters. These amplitudes are the basis
for all relative or absolute concentration calculations.
Methods
Participants
This study was retrospective with the data of a master
thesis in Biology at the Ruhr University of Bochum
(RUB). All participants had given written informed con-
sent. The local ethics committee of the RUB approved
the study and all data evaluations.
Fifty-four spectra pairs were acquired, 28 pairs from
six females and 26 pairs from five males (Table 1). None
of the healthy subjects showed any evidence of a brain
lesion according to the acquired T2-weighted sequences.
All subjects were of similar age. Gender and age were
similarly distributed on the number of subjects as well
as on the number of spectra acquisitions (Table 1).
Spectra acquisition
Subjects were positioned head first, supine with their
head slightly fixed inside the coil. All measurements
were carried out on a Magnetom Espree (horizontal
1.5 T field, wide bore, Siemens Healthcare, Erlangen,
Germany). The signal was received with a 12-channel
head matrix coil and the circularly polarized body coil
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was used for excitation. Firstly, for exclusion of any brain
lesion as well as for spectroscopy voxel placement, T2
weighted axial “Turbo Spin Echo” images of the entire
brain were acquired followed by two (coronal and sagit-
tal) “True Fisp” (true fast imaging with steady state pre-
cession) sequences or a sagittal “True Fisp” and a
coronal “Tirm” (turbo inversion recovery magnitude) se-
quence for voxel placement (sequence parameters in
Table 2).
Two pairs of “point resolved single voxel spectra”
(PRESS) were acquired with identical system parameters
and localized at an identical position on each brain
hemisphere for each subject. Always cubic voxels of
2 cm × 2 cm × 2 cm were selected and placed on the left
and right brain hemisphere central in anterior posterior
direction above the ventricle (marked in Fig. 1 as VOI).
Position and orientation were adjusted to contain white
matter as much as possible. Voxels were placed within
±5 cm relative to the central z-axis position (center of
the magnet in head feet direction). Six saturation pulses
were positioned along each plane of the cube (Fig. 1) for
outer volume suppression (marked in Fig. 1 as num-
bered bars surrounding the VOI). The most effective
one was oriented towards the ventricle (bar 1 in Fig. 1)
and next effective one towards the midline of the
cerebrum (bar 2 in Fig. 1). Prior to paired spectra acqui-
sitions on each side, system parameters were automatic-
ally adjusted and the magnetic field inside the voxel was
homogenized by an automatic shim. Additionally an ex-
perienced operator (MB or SM) optimized shim and
water suppression.
One thousand twenty four data points were sampled
in 512 ms in a two-fold oversampling technique. In the
thesis of MS the short sampling window of 512 ms en-
ables faster repetition times TR for measuring spin–lat-
tice relaxation times T1. The echo time TE was short
(30 ms) and the repetition time TR moderate (1500 ms).
The two spectra of a pair were acquired directly con-
secutive using 128 additions for each spectrum. For sig-
nal evaluation the signal of all 12 channels of the head
coil was used. Total acquisition time on one side was
6:36 min (2 × 3:18 min) preceded by the system param-
eter adjustment time of 7 to 10 min. Total MR time for
each subject was about 30 to 40 min for one session.
Post-processing
The post-processing software “metabolite report” was a
work in progress package from Siemens Healthcare. It is
Table 1 Subject demographics
Healthy subject no Gender Age male Age female No of investiga-tions male
(spectrum pairs)
No of investiga-tions female
(spectrum pairs)
1 f 23.9 4 (8)
2 f 24.9 4 (8)
3 m 24.1 5 (10)
4 f 22.6 2 (4)
5 m 21.2 2 (4)
6 f 22.7 2 (4)
7 m 24.1 2 (4)
8 m 25.9 2 (4)
9 m 23.6 2 (4)
10 f 20.5 1 (2)
11 f 27.7 1 (2)
Mean 23.8 23.7 2.6 (5.2) 2.3 (4.6)
sd 1.7 2.4 1.3 (2.7) 1.4 (2.7)
Mean 23.7 2.5 (4.9)
sd 2.0 1.3 (2.6)
Table 2 Imaging sequence parameters
Sequence name Orientation TR [ms] TE [ms] FA [°] TI [ms] TA [s] FOV [mm x mm] Matrix [points] Slice thick. [mm]
TSE axial 5950 105 55 180 × 240 276 × 512 5
True Fisp cor/sag 4,8 2,4 70° 29 180 × 240 240 × 240 192 × 256 5
Tirm cor 8510 138 2500 ms 60 180 × 240 320 × 512 6
TR repetition time, TE echo time, TI inversion time, FA flip angle, TA acquisition time, FOV field of view
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the precursor of the currently available commercial
spectroscopy software within the new product “syngo
via” and nearly identical to this package (personal com-
munication with Elisabeth Weiland [15], see acknow-
ledgement). “Automated post processing of this software
package consists of the following steps: 1] identification of
the prominent metabolites by cross-correlation to a
database (i.e., N-acetylaspartate (Naa), choline (Cho),
creatine (Cre), myoinositol (Myo) for short echo brain
data), 2] determination of the B0shift and starting values
for the fit parameters, 3] residual water removal, and 4]
fit of the spectroscopic data. The fit is based on a basis
set of metabolic model signals, which are simulated with
the use of literature values for chemical shifts and coup-
ling constants. In addition, truncating and remodeling
of the first data points handle baseline artifacts” [9, 15].
For the analysis of the short TE data of this study, the
following metabolites were included in the fit (major
metabolites are marked bold):





 Glx as a combined Glu/Gln model or separately
fitted Glutamate (Glu) and Glutamine (Gln) with
the sum of both amplitudes as Glx value (in case of
a not found Gln, Glu alone was used as Glx value)
 Two lipid/macromolecule lines around 0.9 and
1.3 ppm in some cases (Lipid_1, Lipid_2)
 GABA (Gamma Amino Butter Acid) in a few cases
Metabolites were modeled as Gauss signals. Only the
lipids were parameterized as Lorentz singlets with indi-
vidual damping (line width) as recommended for short
echo time acquisitions at 1.5 T [16, 17]. All model sig-
nals were filtered by a pass band from 0 to 4.2 ppm to
exclude frequencies outside the area of interest (see
model files in Fig. 2). This pass band filter influences the
amplitude for relative or absolute concentration calcula-
tions by a constant factor respected within the software
metabolite record. For pure reproducibility investiga-
tions a constant factor is not relevant.
For each metabolite the amplitude, the frequency and
the damping (line width) are parameters obtained from
the fit procedure. It is possible to use an individual
phase of each model signal as fit parameter, but as com-
monly accepted a joint phase is used for all metabolites.
The fitted metabolites had to be above the noise level in
Fig. 1 Example of voxel position (VOI) in axial (a), coronal (b) and sagittal (c) images, as well as the saturation regions (numbered from 1 to 6)
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frequency domain by default factor of eight. Otherwise
the metabolite is omitted and the fit is restarted without
this metabolite (personal communication with EW). In
this study the default factor was never changed. The
software marks metabolites chosen for the fit but omit-
ted, because it is too small in signal to noise. For repro-
ducibility evaluation a decision is necessary how to
respect pairs with a one signal above and the other
below the noise level. In our investigation the not found
signal was set to zero. In case of both signals below the
noise level this pair was not respected.
A biochemical concentration is calculated with the fitted
amplitude of a metabolite. Therefore, the post processing
parameters should be optimized to deliver reliable and
most reproducible amplitudes (proportional to metabolite
concentration) for acquisitions assumed to differ only in
noise. The frequency of a metabolite line was adjustable
by the fit algorithm within boundaries to the theoretical
value or it could be referenced to a fixed distance to an-
other metabolite, which frequency can be more easily de-
tected. If the frequency was not fixed to that of another
metabolite the bounds were set to the theoretical value ±
0.1 ppm for all metabolites except the lipids (±0.2 ppm).
The damping could be fitted individually for each metab-
olite or one or more groups of metabolites could have a
common damping. The damping for single metabolites or
a group of metabolites was restricted to values between 1
and 10 Hz except for lipids (1 to 25 Hz, see below).
The separate fit of the CH3 and CH2 creatine lines was
necessary, because the residual water suppression dimin-
ishes the amplitude of the CH2 group disturbing the the-
oretical ratio of 3/2. The water removal consists of an
iterative low pass filter around the frequency at 4.7 ppm
with a fixed number of 22 iterations. At 1.5 T an accur-
ate separation of Glu and Gln is difficult. Therefore Glx
as a combined model with a fixed concentration relation
between both or the sum of separately fitted Glu and
Gln was evaluated as one of the main metabolites. The
baseline was varied using 20 or 50 data points corre-
sponding to 10 or 25 ms, respectively. The two “dummy
lipids” were introduced as additional lines to model the
base line solely below 1.8 ppm. These lipid lines incorp-
orate macromolecules.
For detecting the most reproducible results using pairs
of consecutive acquisitions with identical system param-
eters, no relaxation corrections had to be applied to the
Fig. 2 Model metabolites in frequency domain for a 30 ms PRESS sequence calculated with NMR-Scope of jMRUI using a damping of 2 Hz [10, 11].
(Chemical structures build with free Chemscetch from ACD Labs, Toronto, Canada)
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fitted amplitudes. It is sufficient to examine the un-
changed amplitudes from which relative or absolute con-
centrations can be calculated. The error most likely
increases (reproducibility decreases) with corrections
and/or evaluation of absolute concentrations [mmol/l]
or relative concentrations referenced to another metab-
olite. Both relaxation corrections as well as evaluation of
concentrations involve measured or assumed values in-
creasing the concentration errors.
Reproducibility calculations
Reproducibility is calculated with two directly consecu-
tive acquired spectra (a pair) on one side of the brain.
They are identical concerning the biochemical metabol-
ite basis including the ones with a short T2 simulated as
base line and they coincide in system parameter settings.
For concentration independent quantification of the re-
producibility the normalized squared difference of a pair
is calculated. The possible range of the normalized dif-
ference is between −2 and 2. Case of “±2” consists of a
zero and a non-zero value, which means the non-zero
value is 200 % of the mean value. Typical values are
much smaller than 1 for each main metabolite. The root
of the mean value of all acquired pairs defines the nor-
malized root mean square deviation, which simply is
designated as reproducibility number rn (Eq. 1).






ampi2 metð Þ−ampi1 metð Þ
 
ampi2 metð Þ þ ampi1 metð Þ=2
 
 !2vuut ð1Þ
rn(met): reproducibility number; normalized root mean
square deviation for metabolite “met”
N: number of acquisition pairs
ampij(met): amplitude of metabolite met for acquisition
pair with index i. The index within a measurement pair
is j = 1, 2.
The “reproducibility number” rn(met) describes the
mean relative (percentage) deviation between N meas-
urement pairs for metabolite met. So a low rn(met) value
means a good reproducibility of metabolite met.
For the calculation of rn no reference is necessary to ex-
clude different system settings, because the compared
values of a pair were acquired with identical parameters.
Normalization to the mean value was used to ease the re-
producibility comparison between different metabolites.
Firstly the reproducibility is tested with only one
spectrum pair of the eleven subjects. The first acquisition
pair on the left-brain hemisphere is evaluated using the
parameters specified in table 3 for 25 different protocols.
As measure of reproducibility for all metabolites the
added rn percentage value of Naa, Cre3, Cho, Myo and
Glx was used (Table 3). Other sums of rn with less metab-
olites were also calculated for overall reproducibility
rating. Post processings with a low sum (marked under-
lined and italic Table 3) were evaluated for all 54 pairs
(Table 4).
Additionally the metabolite amplitudes for the proto-
cols with the best reproducibility were referenced to the
amplitude of Cre3 (ampref(met) = amp(met)/amp(Cre3))
to check the influence on this step to the reproducibility.
In principal an unlimited number of different post-
processing protocols are possible. Hence in this investi-
gation the protocols were varied to answer the following
questions.
Is the reproducibility increased or decreased by the use of:
Table 3 Description of tested protocols
Protocol no Glx Glu/Gln GABA Li’s Base com. dam. full eval.
0 free – – – 25 ms – –
1 free – free free 25 ms – –
1a free – – free 25 ms – –
2 free – – – 10 ms – –
3 free – free free 10 ms – –
3a free – – free 10 ms – –
4 – free – – 25 ms – –
5 – free free free 25 ms – –
5a – free – free 25 ms – –
6 – free – – 10 ms – +
7 – free free free 10 ms – –
7a – free – free 10 ms – –
8 – Naa – – 25 ms – –
9a – Naa – free 25 ms – –
10 – Naa – – 10 ms – +
11a – Naa – free 10 ms – –
12 – free – – 25 ms + +
13a – free – free 25 ms + +
14 – free – – 10 ms + +
15a – free – free 10 ms + –
16 – Naa – – 25 ms + –
17a – Naa – free 25 ms + –
18 – Naa – – 10 ms + +
19a – Naa – free 10 ms + +
20 – Naa – free 10 ms + Myo free –
Amplitude and frequency of Naa, Cre3, Cre2, Cho and Myo are always fit
parameters. The damping for each metabolite is independent in case of a “–”
in column “common damping” and equal for all metabolites except the lipids
and Cre2 in case of a “+”. The damping of these metabolites can be adjusted
between 1 and 10 Hz. The damping of lipids is always independent with
range from 1 to 25 Hz. “full evaluation” means all 54 pairs of spectra were
used for rn evaluation, whereas in other cases only one spectrum of each
subject (11 examples, left brain hemisphere of first investigation) was used for
an estimation of rn. Naa means the frequency of Glu/Gln is fixed relative to
the detected frequency of Naa. The numbering follows the historical order of
evaluation and therefore needs in some cases an index “a” for later
evaluated protocols
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1. additional low signal to noise metabolites beside the
major metabolites?
To answer this question as example GABA was
used with peaks in between 2 and 3 ppm (Fig. 3a).
N-Acetyl Aspartyl Glutamate (NaaG) was also
investigated, but in this case the Naa evaluation was
distorted too much even using the sum of Naa and
NaaG (Fig. 3c) and therefor was not further respected.
2. separately fitted glutamate and glutamine values
instead of a predefined Glx model?
3. a flat or a more curved baseline using the first 10 or
25 ms for the base line calculation?
Table 4 Reproducibility results using 11 left brain pairs of spectra from eleven subjects
Glx all metabolites with free parameter Glu. Gln ref Naa
Protocol 0 1 1a 2 3 3a 8 09a 10 11a
Naa 3.1 8.8 2.9 4.4 16.4 5.5 2.9 2.9 3.3 3.2
Cre3 5.4 6.0 5.5 5.3 7.6 5.9 5.4 5.5 5.6 5.5
Cho 4.5 6.1 4.7 4.6 11.0 7.6 4.4 4.4 4.7 7.2
Myo 8.3 9.8 9.7 17.4 52.6 46.5 6.8 6.4 11.3 33.5
Glx 153.1 167.5 159.0 82.0 127.1 115.6 13.6 12.8 5.2 5.0
all 174.4 198.3 181.7 113.7 214.7 181.1 33.2 31.9 30.1 54.4
Naa. Cre3. Cho 13.0 21.0 13.1 14.2 35.0 19.0 12.8 12.7 13.6 15.9
all–Myo 166.1 188.4 172.0 96.3 162.1 134.6 26.4 25.5 18.8 20.9
all–Glx 21.3 30.8 22.7 31.6 87.6 65.6 19.6 19.1 24.9 49.4
Mean χ2 3819 3617 3839 5574 4731 5120 3742 3765 5040 4941
Glu. Gln all metab. with free parameter Glu. Gln. all free + co. dam.
Protocol 4 5 5a 6 7 7a 12 13a 14 15a
Naa 3.3 12.0 3.4 4.7 9.8 7.7 2.9 2.8 3.2 5.2
Cre3 5.3 4.8 5.3 5.3 5.9 5.1 4.3 4.3 5.1 5.5
Cho 4.2 5.4 4.1 4.1 8.6 5.1 3.7 3.6 3.3 5.5
Myo 13.8 15.9 12.1 6.4 39.9 31.1 6.3 5.1 8.7 17.3
Glx 25.9 25.0 22.8 5.0 14.4 7.5 13.1 12.1 6.1 6.9
all 52.5 63.0 47.8 25.4 78.6 56.4 30.3 27.9 26.3 40.3
Naa. Cre3. Cho 12.8 22.1 12.8 14.0 24.3 17.8 10.9 10.7 11.5 16.2
all–Myo 38.7 47.1 35.6 19.1 38.7 25.3 24.0 22.8 17.6 23.1
all–Glx 26.6 38.0 24.9 20.4 64.2 48.9 17.2 15.8 20.2 33.5
Mean χ2 3651 3475 3751 4773 4399 4667 3757 3786 5041 4891
Glu. Gln ref Naa + common damping
Protocol 16 17a 18 19a 20
Naa 2.8 2.7 3.2 3.1 3.0
Cre3 4.4 4.4 5.2 4.9 4.9
Cho 3.5 3.5 3.3 3.4 4.7
Myo 5.2 5.2 10.8 11.1 6.9
Glx 22.4 23.2 6.2 5.8 29.9
all 38.3 39.0 28.7 28.4 49.4
Naa. Cre3. Cho 10.7 10.7 11.7 11.4 12.6
all–Myo 33.1 33.9 17.9 17.2 42.5
all–Glx 15.9 15.8 22.5 22.6 19.6
Mean χ2 3856 3886 5237 5138 5046
The minimal values for each of the five main metabolites are marked bold. “Sums” of all five metabolite rn’s below 31 are marked underlined italic. These eight
protocols are investigated for all 54 pairs of spectra. The mean χ2 value is calculated from the 22 Siemens post processing χ2 of the fit procedures necessary to
calculate the rn of 11 pairs. Note: all values in percent except for mean χ2
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Fig. 3 Fit (red) of the same data (white) calculated with protocol 5 resulting in a “flat” (a) and with protocol 18 with a “less flat” difference line
(green) (b). The baseline is orange. χ2 calculated by the post processing software was 3348 (a) and 5122 (b), respectively and is a little less than
the mean values of Table 3. Image (c) shows the distorted Naa evaluation with NaaG as additional metabolite. A:, P: and W: are the amplitude of
a metabolite, its frequency in ppm and its line width in Hz. Note: the lipid amplitudes inside healthy brain tissue are very small compared to that
of tumors. In most cases, depending on the protocol, no or only one lipid line was detected. This is also documented by both protocols with the
best reproducibility (protocol 14 and 18), which did not use lipid models
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4. an independent damping for each metabolite or a
common damping for the major metabolites?
5. common damping for major metabolites except for
Myo, because its frequency is near the water
frequency?
6. two additional lipid/macromolecule signals below
1.8 ppm as additional support for the baseline?
7. the frequencies of glutamate and glutamine as
independent fit parameters or the use of fixed
frequencies in relation to the most prominent
metabolite line of Naa?
8. relative amplitudes (referencing the metabolites to
Cre3)?
Results
The results using 11 pairs of acquisitions are summa-
rized in Table 3. The protocol with the lowest χ2 is, as
expected, No 5, the one using the most metabolites with
freely adjustable parameters. In contrast to the lowest χ2
protocol 5 is not in the top category concerning the
reproducibility.
The flow chart of Fig. 4 shows the strategy for the
evaluation of the best protocols using eleven pairs, one
from each participant. For each question protocols with
a significantly lower reproducibility performance were
ruled out from further questions. Compared protocols
with a difference in the sum of all rn numbers lower
than 3 % were defined as similar and both were used for
further investigations. Protocols 6, 9a, 13a, 14, 18, 19a
are left after this decision process. These protocols ex-
cept 9a were investigated with all 54 pairs for the detec-
tion of the best reproducibility. 9a was replaced for total
evaluation by the more reproducible protocols 10 and
12. These seven protocols have the best reproducibility
sum (< 31 %) of all main metabolite.
The protocols with the best results using all 54 pairs
were protocols 14 and 18 (Table 4 and Fig. 3b).
Protocols to compare for each question are listed in
the flow chart of Fig. 4. Concerning the prior defined
questions the results are as follows.
1. Is the reproducibility increased or decreased by the
use of additional metabolites beside the clearly
visible metabolites at 1.5 T?
Question 1 is investigated by comparing identical
protocols differing only in the use of GABA.
Protocols 1, 3, 5, 7 used GABA as an additional
metabolite, whereas the protocols 1a, 3a, 5a, 7a
excluded GABA. The protocols without GABA gave
a better reproducibility as indicated by a smaller
sum of the reproducibility numbers of the five
major metabolites (see Fig. 4). Also the mean χ2 is,
except for protocol five, less in the protocols
without GABA.
2. Is the reproducibility increased or decreased by the
use of the sum of separately fitted glutamate and
glutamine values instead of a predefined Glx model?
Fig. 4 Decision flow chart showing the protocols tested on eleven
pairs towards an increasing reproducibility
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The comparison shows, that the use of the sum of
separately fitted glutamate and glutamine values
yields in all cases a much better reproducibility than
in the six cases of a predefined Glx model.
3. Is the reproducibility increased or decreased by the
use of a “flat” or a more “curved” baseline using the
first 10 ms or 25 ms for the base line calculation,
respectively?
Using only the protocols not ruled out by
question 1 and 2 the use of a more flat base line is
generally better (protocols 5a, 6, 9a, 10, 13a, 14, 18
and 19a are better than protocols 7a, 4, 11a, 8, 15a,
12, 16, 17a).
4. Is the reproducibility increased by the use of an
independent damping for each metabolite or a
common damping for the major metabolites?
On the basis protocol 6, 10, 14, 18 no decision is
possible (protocols 6 and 18 are slightly better than
protocols 14 and 10).
5. Is the reproducibility increased by the use of a
common damping for the major metabolites (see 4)
except for Myo?
The use of a freely adjustable damping for Myo and
a common damping for Naa, Cre3, Cho and Glx
gave less reproducible results than the inclusion of
Myo in the common damping (compare Table 3
protocol 20 and 19a).
6. Is the reproducibility increased by the use of two
additional lipid/macromolecule signals below
1.8 ppm as additional support for the baseline?
On the basis protocol 5a, 6, 18, 19a no decision is
possible (protocol 6 is much better than 5a and
protocol 19a is not significantly better than 18).
7. Is the reproducibility increased or decreased by the
use of the frequencies of glutamate and glutamine as
independent fit parameters or the use of fixed
frequencies in relation to the most prominent
metabolite line of Naa?
On the basis protocol 6, 10, 14, 18 no definite
decision possible. Protocol 14 is slightly better than
18 and 6 is better than 10.
8. Is the reproducibility changed by the calculation of
relative amplitudes (normalizing the metabolites
using Cre3 as reference)?
The normalization is a division of two amplitudes
with errors. So it is expected that the reproducibility
is rather decreased by normalization. The largest
decrease is found for Naa. For Cho and Glx the
reproducibility is slightly decreased, whereas for
Myo no relevant increase is found (see Table 4; 14,
18 vs. 14 ref, 18 ref ). The reproducibility for
normalized Naa, Cho and Glx was around 5 %
whereas the reproducibility for Myo was close but
above 9 % (Table 4).
Protocols 6, 9a, 13a, 14, 18, 19a are left after this deci-
sion process.
These remaining protocols except 9a were inves-
tigated with all 54 pairs for the detection of the best re-
producibility. 9a was replaced for total evaluation by the
more reproducible protocols 10 and 12. Summarizing
the results of Table 4 using all 54 pairs, the protocols
with most reproducible results for Naa, Cre3, Cho, Myo
and Glx in lesion free white matter (protocols 14 and
18) have the following common features: no additional
metabolites, Glx is taken as the sum of separately fitted
Glu and Gln, a baseline modeled with the points of the
first 10 ms, no additional lipid lines, common damping
of all metabolites.
Discussion
This investigation uses in vivo data for reproducibility
assessment. An alternative would be the use of a set of
theoretical metabolite bases with added statistical noise.
The advantage of in vivo data from eleven individuals at
different brain sides and different time points lays in the
realistic concentration variation of the metabolite basis
and the immanent use of non “visible” metabolites with
a poor signal to noise ratio.
In contrast to other studies on reproducibility or vari-
ability [18–24] this investigation did not calculate the
coefficient of variation for intra or inter subject reprodu-
cibility or variation depending on the location inside the
brain. Instead two acquisitions with different noise and
an identical metabolite basis are investigated for 54 pairs
on their coincidence regarding the amplitudes of the
main metabolites.
The protocols with the best results using all 54 pairs
were protocols 14 and 18 (Table 4). Protocol 18 is favor-
able, mainly because protocol 18 achieves the same re-
producibility as 14 with two parameters less: the
frequencies of Glu and Glu were fixed in relation to the
frequency of Naa. Additionally, in the reference version
of protocol 18, 18ref, the reproducibility number rn of
the pairs individually referenced to Cre3 as well as the
sum of all rn’s were less for all cases except Cho in com-
parison to 14 ref.
The amplitudes of the metabolites strongly depend on
the fitted baseline as also described by Hofmann et al.
[25]. Depending on the curvature the values can differ
significantly. In Fig. 3a for example the baseline had a
broad peak between the lines of Cre2 and Cre3 and
therefore the amplitude value (f. e.) for Cho is low in
contrast to Fig. 3b with a more flat and lower baseline in
this region.
This study did not vary all possible parameters. Add-
itionally some parameters should have more steps. For
example, using only the data of the first 10 or 25 ms for
the base line were used; further investigations with
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additional times may improve the reproducibility. The
default minimal signal to noise ratio for the amplitude of
a metabolite was eight and never changed (see
“Methods”). But every boundary in the signal to noise
ratio–independent of the value–can impede the detec-
tion of a metabolite in only one of the two spectra build-
ing a pair. In such a case the normalized squared
difference is large (four) assuming the not detected sig-
nal amplitude as zero (Eq. 1). This explains the large rn
values for Glx in protocols 0 to 5a. Using protocols 0 to
3a (Table 5) in some cases the combined Glx was found
only in one of the two spectra, whereas in case of
protocol 4 to 5a this happened only for Gln with a
lower signal to noise ratio compared to Glu, which was
found in every case. A missing Gln in one of a pair in-
creases the reproducibility number rn much less, than
in the case of Glx.
The residual water suppression in this study was im-
plemented as an iterative filter with 22 stages. The ex-
perience of the user (MB) preferred this value instead of
the default value of 10. No other stage numbers have
been tested, because recent post processing software al-
gorithms (jMRUI [11, 26–29] or Syngo Via (Siemens
Healthcare)) prefer instead of an iterative filter a singular
value decomposition (SVD) algorithm for residual
water suppression. This was not possible with the work
in progress software metabolite report, but both
methods are available in the final product Syngo Via.
The comparison of SVD and iterative filter within
Syngo Via is not done yet.
This study did not examine absolute metabolite con-
centrations. Only the amplitudes or relative amplitudes
with Cre3 as reference (ampmet/ampCre3) of directly
comparable pairs were evaluated. The reason on one
hand is the intention to search for an optimized repro-
ducibility not needing a reference with a known concen-
tration. On the other hand the reason is the lack of
consensus for acquisition and post-processing methods
to evaluate absolute metabolite concentration. Published
results show “considerable variations in the approaches”
[8] and therefore a large span for absolute concentra-
tions. For the metabolite Naa with the best reproducibil-
ity, the concentration inside white matter in healthy
subjects can differ from 9.7 to 18.4 mmol/l [30–34]. The
values depend on sequence design, acquisition system,
post-processing algorithm as well as post-processing pa-
rameters, relaxation corrections, internal or external ref-
erences or subject gender, subject age and the position
inside the brain [24].
All spectra of this investigation were acquired in “le-
sion free” (no lesion signs found in MR imaging) white
matter brain tissue. Spectra of brain lesions, for example
tumors, can be drastically different. For example the
lipid components in/around high-grade brain tumors
normally are extremely large compared to the small
(often zero) values found in healthy tissue. In our exam-
ination the detected lipids were very small and superim-
posed or dominated by macromolecules. In most of our
pairs no or only one lipid line was found as expected for
healthy subjects without a sign for any brain disease.
For that reason the application of the post processing
parameters of this investigation is limited to lesion free
tissue. But despite of this limitation the application to
studies is broad, because alterations in brain biochemis-
try of lesion free areas had been detected nearby
tumors [35–37], in patients with multiple sclerosis [38],
Table 5 Reproducibility calculated as rn in percent for 54 pairs
of consecutive spectra





Naa 4.4 2.3 2.5 2.5 3.1 4.5 2.2 4.2 2.3
Cre3 4.9 4.7 4.3 4.5 4.4 0 4.3 0 4.4
Cho 5.3 5.3 4.7 4.7 4.1 4.9 4.8 5.2 4.9
Myo 12.9 23.7 10.0 11.3 9.3 9.1 9.0 9.0 9.7
Glx 7.7 5.7 12.9 13.5 4.6 6.0 5.2 5.7 5.5
Sum of all
met.
35.1 41.8 34.4 36.4 25.5 24.5 25.5 24.2 26.8
Naa, Cre3,
Cho
14.5 12.4 11.5 11.7 11.6 (9.4) 11.3 (9.4) 11.6
all–Myo 22.2 18.2 24.4 25.2 16.2 15.4 16.5 15.1 17.1
all–Glx 27.4 36.1 21.5 23.0 20.9 18.5 20.3 18.5 21.3
amp.(Naa) 190.8 206.9 181.0 180.4 200.0 1.9 208.2 2.0 209.0
amp.(Cre3) 96.5 95.9 97.3 97.5 104.5 1 105.4 1 106.5
amp.(Cho) 28.2 28.5 29.4 29.3 31.5 0.3 31.7 0.3 32.0
amp. (Myo) 55.3 66.9 57.1 57.9 68.4 0.6 71.5 0.7 71.4
amp. (Glx) 226.5 279.7 155.9 159.7 322.3 3.1 261.8 2.5 255.7
±% of
mean
Naa 13.1 6.1 6.4 6.3 8.01 12.8 6.3 11.1 6.3
Cre3 11.2 13.2 11.7 11.5 10.9 0.0 11.4 0.0 11.1
Cho 11.9 13.8 13.8 14.4 10.0 15.2 13.9 18.3 13.3
Myo 57.2 88.2 35.7 50.2 34.0 33.4 28.2 28.2 28.9
Glx 21.2 16.2 29.2 30.8 11.9 14.9 13.3 12.0 13.5
The minimal values for each of the five main metabolites are marked bold. The
values of the referenced metabolites are in italic. Protocol 18 shows up together
with protocol 14 the best reproducibility rated by the sum of the five rn’s of the
main metabolites. Protocol 18 is preferable, because
1. it needs less fit parameters for identical reproducibility results
2. the rn sum of the major metabolites is minimal for 18 ref, because rn of
Cre3 is minimal in protocol 18
Note: In all cases the rn calculated with 54 pairs is similar as in the case of 11
pairs (compare Table 3 with Table 4). This legitimates the missing calculations
with all 54 pairs for the protocols not enlisted in Table 4
“ref” indicates that the amplitude of a metabolite is referenced to Cre3, which
is the calculation of relative concentrations i.e.
evaluatedas ampref(met) = amp(met)/amp(Cre3)
“±% of mean” for each metabolite (five last lines) is the maximal percentage
deviation from the mean value for a pair of amplitudes
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drug abuse [39–41], AIDS [42, 43] or psychiatric
disorders [44].
Conclusion
The prerequisites of this study were optimal for in vivo
comparisons. The brain is one of the organs that can be
easily fixed inside the scanner. Spectrum pairs were ac-
quired within a few minutes guaranteeing a stable me-
tabolite basis for comparisons. All pairs were similar,
because only lesion free white matter of healthy subjects
at an identical brain position was investigated.
Metabolite amplitudes inside lesion free healthy brain
can be quantified with a calculated accuracy (rn(met))
around 5 % for Naa, Cho and Glx using Cre3 as refer-
ence. The reproducibility of Myo is roughly twice as bad.
Assuming these rn, the real metabolite amplitudes calcu-
lated with these post-processing parameters are most
likely within a twofold interval of ±10 or ±20 % respect-
ively. The reproducibility (rn) should be similar using
other references like internal or external water for an ab-
solute concentration evaluation and are not influenced
by relaxation corrections with literature values, which is
only a multiplication by a constant factor.
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